002821.SHE Asymchem Laboratories Tian Jin Co Ltd
- Market cap
- CNY 49.0B
- P/E
- 39.7x
- P/B
- 2.74x
- ROE
- 6.4%
- Dividend yield
- 0.81%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002821.SHE undervalued?
Graham number002821.SHE trades 119.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Asymchem Laboratories Tian Jin Co Ltd fundamental analysis
No fundamental analysis for Asymchem Laboratories Tian Jin Co Ltd yet.
Asymchem Laboratories Tian Jin Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Asymchem Laboratories Tian Jin Co Ltd
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic bio…
Full company profileAsymchem Laboratories Tian Jin Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Asymchem Laboratories Tian Jin Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.10B | 1.42B | 1.83B | 2.46B | 3.14B | 4.63B | 10.2B | 7.83B | 5.80B | 6.67B | 7.19B |
| Gross Profit | 569M | 736M | 853M | 1.12B | 1.45B | 2.05B | 4.83B | 3.99B | 2.41B | 2.80B | 3.01B |
| Operating Income | 315M | 420M | 461M | 624M | 767M | 1.07B | 3.11B | 2.57B | 1.08B | 1.25B | 1.43B |
| EBITDA | 357M | 495M | 496M | 666M | 922M | 1.24B | 3.43B | 2.65B | 1.07B | 1.85B | 1.28B |
| Net Income | 253M | 341M | 428M | 554M | 720M | 1.07B | 3.30B | 2.27B | 949M | 1.13B | 1.14B |
| EPS | 0.99 | 1.06 | 1.33 | 1.71 | 2.19 | 3.13 | 9.00 | 6.26 | 2.69 | 3.14 | 3.14 |
| Balance Sheet | |||||||||||
| Total Assets | 2.44B | 2.64B | 3.19B | 3.76B | 7.18B | 15.2B | 18.2B | 19.8B | 19.3B | 20.3B | 21.6B |
| Total Liabilities | 612M | 482M | 675M | 713M | 1.19B | 2.55B | 2.54B | 2.26B | 2.43B | 2.63B | 3.82B |
| Shareholders' Equity | 1.75B | 2.06B | 2.51B | 3.05B | 5.99B | 12.6B | 15.6B | 17.5B | 16.8B | 17.6B | 17.8B |
| Cash & Short-term Investments | 1.08B | 839M | 637M | 435M | 2.12B | 6.64B | 7.44B | 9.02B | 7.33B | 6.32B | 4.18B |
| Total Debt | 186M | 152M | 123M | 90.5M | 35.9M | 421M | 110M | 119M | 283M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 278M | 196M | 415M | 601M | 569M | 113M | 3.29B | 3.55B | 1.25B | 1.41B | - |
| Capital Expenditure | 236M | 303M | 543M | 511M | 1.01B | 1.66B | 2.15B | 1.24B | 1.13B | 1.27B | 1.88B |
| Free Cash Flow | 42.0M | -107M | -128M | 90.1M | -446M | -1.55B | 1.14B | 2.31B | 124M | 137M | -1.07B |
| Ratios | |||||||||||
| ROE | 14.4% | 16.6% | 17.1% | 18.2% | 12.0% | 8.5% | 21.1% | 13.0% | 5.6% | 6.4% | 6.4% |
| ROA | 10.3% | 12.9% | 13.4% | 14.7% | 10.0% | 7.1% | 18.1% | 11.5% | 4.9% | 5.6% | 5.3% |
| Net Profit Margin | 22.9% | 24.0% | 23.3% | 22.5% | 22.9% | 23.1% | 32.3% | 29.0% | 16.3% | 17.0% | 15.8% |
| Debt to Equity | 0.11x | 0.07x | 0.05x | 0.03x | 0.01x | 0.03x | 0.01x | 0.01x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Asymchem Laboratories Tian Jin Co Ltd dividends
- Dividend yield
- 0.81%
- Forward dividend
- 1.30 CNY
- Payout ratio
- 34.9%
- Ex-dividend date
- Jun 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 395M | 1.10 | 34.9% |
| 2024 | CNY 642M | 1.82 | 67.6% |
| 2023 | CNY 664M | 1.83 | 29.3% |
| 2022 | CNY 211M | 0.58 | 6.4% |
| 2021 | CNY 146M | 0.43 | 13.6% |
| 2020 | CNY 116M | 0.35 | 16.1% |
| 2019 | CNY 92.5M | 0.29 | 16.7% |
| 2018 | CNY 80.5M | 0.25 | 18.8% |
| 2017 | CNY 59.1M | 0.18 | 17.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jul 21, 2022.
Who owns Asymchem Laboratories Tian Jin Co Ltd
- Insiders 40.92%
- Institutions 23.36%
- Public & others 35.72%
- Shares outstanding 334M
- Free float 223M
Asymchem Laboratories Tian Jin Co Ltd company profile
- Company name
- Asymchem Laboratories Tian Jin Co Ltd
- Ticker
- 002821.SHE
- ISIN
- CNE100002BZ6
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 10,617
- Fiscal year end
- December
- Address
- No. 71, Seventh Avenue, Tianjin, China, 300457
- Phone
- 86 22 6638 9560
- Website
- asymchem.com.cn
About Asymchem Laboratories Tian Jin Co Ltd
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic biology and new technology output business. The company also engages in key pharmaceutical intermediates, APIs, and formulations activities. The company was founded in 1998 and is headquartered in Tianjin, China.
Asymchem Laboratories Tian Jin Co Ltd management
10- Dr. Hao Hong Ph.D.Founder, Chairman & CEO · born 1956
- Ms. Rui YangCo-CEO & Executive Director · born 1977
- Mr. Da ZhangCFO, COO, Senior VP & Executive Director · born 1981
- Mr. Jiang YingweiExecutive Vice President of Human Resources & Administration · born 1977
- Dr. Liang HongExecutive VP & Executive Director · born 1974
- Mr. Chaoyong ChenExecutive Vice President of Manufacturing & Tech Transfer · born 1982
- Dr. Yan ZhouSenior Vice President of Quality Management · born 1979
- Dr. Chen Yi ChengCTO of the Small-Molecule Sector · born 1964
- Mr. Xiangke XuSenior Vice President and Board Secretary of Public Affairs & Regulatory Affairs & Legal Affairs · born 1979
- Mo HuangAccounting Supervisor